Lotte Biologics announced on Monday that it will participate in Drug, Chemical & Associated Technologies Association (DCAT) Week, a global pharmaceutical and biotech industry business event, taking place in New York from March 23 to 26.
DCAT Week is a premier international networking event for the pharmaceutical and biotech sectors, held annually in New York. It serves as a platform for global pharmaceutical companies and Contract Development and Manufacturing Organizations (CDMOs) to explore collaborative opportunities.
Lotte Biologics will operate a dedicated meeting room at the Lotte New York Palace Hotel, where the event is being held. The company aims to actively pursue global CDMO business partnerships, with a focus on the North American market.
In its collaborative discussions, Lotte Biologics plans to highlight the synergy between the established quality competitiveness of its Syracuse Bio Campus in New York and the large-scale production capabilities of its first factory in Songdo, Incheon, which is set to be completed in August.
The company will also emphasize its efforts to enhance service delivery capabilities through strategic collaborations. It will showcase its partnership with ASIMOV, established in March last year, which enables the completion of processes from cell line development to active pharmaceutical ingredient production in approximately 8.5 months.
Furthermore, Lotte Biologics will underscore its support for the development and manufacturing of various modalities, including monoclonal antibodies and bispecific antibodies. The company will also highlight its step-by-step manufacturing options, covering everything from clinical trials to drug manufacturing and quality (good manufacturing practice (GMP)) approval production.
A spokesperson for Lotte Biologics stated that DCAT Week is a crucial event that brings together key decision-makers in the global pharmaceutical and biotech industries. Through the participation, it plans to actively seek collaboration opportunities with potential clients and continue to expand the competitiveness in the global market.
